ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death
Erasca, Inc. (ERAS) shares dropped nearly 40% after-hours following a treatment-related death in a Phase 1 study of its cancer therapy ERAS-0015, despite positive early tumor response rates. The patient, a 66-year-old with pancreatic cancer, died after developing pneumonitis. The company reported strong response rates in lung and pancreatic cancers and plans to advance to expansion studies. Additionally, Erasca faces patent infringement allegations from Revolution Medicines regarding ERAS-0015.
How this was made
The 30-second read
Why it matters
The adverse event could trigger a clinical hold, affect regulatory timelines, and depress the stock sharply.
Market read
The safety issue directly caused a near‑40% after‑hours decline, making the news highly relevant for traders.
What to watch
Strong early tumor response rates and ctDNA reductions may support longer‑term upside despite the safety setback.
Background
Erasca disclosed a Grade 3 pneumonitis leading to a treatment‑related death in its Phase 1 ERAS‑0015 study.
Ticker impact
Safety disclosure of a treatment‑related death caused ERAS stock to plunge ~40% in after‑hours trading.
Further downside pressure expected as investors reassess risk.
A fatal adverse event in a Phase 1 KRAS‑mutant trial is material and likely to trigger regulatory scrutiny and investor sell‑off.
Market effects
Caution may spread to other KRAS‑targeted biotech firms and early‑stage oncology pipelines.
US biotech sector could see heightened volatility.
International investors tracking KRAS therapies may adjust exposure.
Counterpoint
If the trial resumes without further events, the steep price drop could present a deep‑value entry.
Key entities
- companyErasca, Inc.
Biotech firm developing KRAS‑mutant cancer therapies.
- companyRevolution Medicines
Filed a patent infringement claim against Erasca.
